ArticlePloS one2024

Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction.

Yi Jing Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.